| Medical and Health Sciences | Lifetime | 257 | US 138 | 99.99 |
| Hematology | Lifetime | 3 | US 3 | 99.98 |
| Molecular Biology | Lifetime | 312 | US 205 | 99.86 |
| Oncology | Lifetime | 156 | US 84 | 99.74 |
| Medical Genetics | Lifetime | 242 | US 121 | 98.05 |
| Immunology | Lifetime | 895 | US 455 | 96.98 |
| Cancer Research | Lifetime | 731 | US 377 | 94.86 |
| Pathology and Forensic Medicine | Lifetime | 936 | US 421 | 95.30 |
| Medical Biochemistry | Lifetime | 554 | US 159 | 82.05 |
| Hematology | 2021-2025 | 64 | US 34 | 98.63 |
| Oncology | 2021-2025 | 443 | US 197 | 94.62 |
| Immunology | 2021-2025 | 631 | US 227 | 81.50 |
| Peptidase Inhibition and Analysis | Lifetime | 1 | US 1 | 99.99 |
| Multiple Myeloma Research and Treatments | Lifetime | 1 | US 1 | 99.99 |
| Protein Degradation and Inhibitors | Lifetime | 1 | US 1 | 99.98 |
| Ubiquitin and proteasome pathways | Lifetime | 2 | US 2 | 99.97 |
| Cancer Mechanisms and Therapy | Lifetime | 3 | US 2 | 99.88 |
| Histone Deacetylase Inhibitors Research | Lifetime | 12 | US 10 | 99.81 |
| Cancer Treatment and Pharmacology | Lifetime | 61 | US 35 | 99.76 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 111 | US 65 | 99.64 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 296 | US 184 | 99.40 |
| Chemokine receptors and signaling | Lifetime | 38 | US 17 | 99.08 |
| Cancer therapeutics and mechanisms | Lifetime | 147 | US 86 | 99.06 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 129 | US 75 | 98.76 |
| Immunotherapy and Immune Responses | Lifetime | 581 | US 308 | 99.06 |
| Hematopoietic Stem Cell Transplantation | Lifetime | 232 | US 133 | 98.96 |
| Glycosylation and Glycoproteins Research | Lifetime | 499 | US 235 | 98.42 |
| CAR-T cell therapy research | Lifetime | 435 | US 268 | 98.72 |
| Lymphoma Diagnosis and Treatment | Lifetime | 521 | US 249 | 98.68 |
| Blood transfusion and management | Lifetime | 109 | US 62 | 97.94 |
| Bone health and treatments | Lifetime | 417 | US 182 | 98.03 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | Lifetime | 324 | US 140 | 97.57 |
| Cell death mechanisms and regulation | Lifetime | 497 | US 206 | 96.63 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 710 | US 312 | 97.01 |
| Retinoids in leukemia and cellular processes | Lifetime | 924 | US 443 | 93.67 |
| 14-3-3 protein interactions | Lifetime | 949 | US 356 | 76.14 |
| Beetle Biology and Toxicology Studies | Lifetime | 427 | US 108 | 62.92 |
| Multiple Myeloma Research and Treatments | 2021-2025 | 44 | US 17 | 99.42 |
| Peptidase Inhibition and Analysis | 2021-2025 | 78 | US 22 | 98.06 |
| Protein Degradation and Inhibitors | 2021-2025 | 68 | US 33 | 98.48 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 381 | US 127 | 94.12 |
| CAR-T cell therapy research | 2021-2025 | 830 | US 445 | 95.29 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 596 | US 262 | 94.16 |
| Ubiquitin and proteasome pathways | 2021-2025 | 488 | US 125 | 87.49 |
| Histone Deacetylase Inhibitors Research | 2021-2025 | 870 | US 242 | 75.47 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 399 | US 141 | 73.79 |
| Adenosine and Purinergic Signaling | 2021-2025 | 921 | US 152 | 62.35 |
| Chemokine receptors and signaling | 2021-2025 | 677 | US 135 | 55.82 |
